Syndax Pharmaceuticals, Inc. Stock price
Equities
SNDX
US87164F1057
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.8 USD | +3.16% | +4.02% | +10.13% |
Financials (USD)
Sales 2024 * | 31.42M | Sales 2025 * | 121M | Capitalization | 2.02B |
---|---|---|---|---|---|
Net income 2024 * | -312M | Net income 2025 * | -251M | EV / Sales 2024 * | 55.1 x |
Net cash position 2024 * | 291M | Net cash position 2025 * | 223M | EV / Sales 2025 * | 14.8 x |
P/E ratio 2024 * |
-6.37
x | P/E ratio 2025 * |
-8.61
x | Employees | 184 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.24% |
Latest transcript on Syndax Pharmaceuticals, Inc.
1 day | +3.16% | ||
1 week | +4.02% | ||
Current month | +1.54% | ||
1 month | -0.34% | ||
3 months | +10.24% | ||
6 months | +52.27% | ||
Current year | +10.13% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Metzger
CEO | Chief Executive Officer | 53 | 15-05-04 |
Peter Ordentlich
FOU | Founder | 55 | 05-10-10 |
Neil Gallagher
PSD | President | - | 23-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 17-03-28 |
Dennis Podlesak
CHM | Chairman | 66 | 08-11-30 |
Pierre Legault
BRD | Director/Board Member | 63 | 17-01-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.12% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 23.8 | +3.16% | 1,058,374 |
24-03-27 | 23.07 | +7.60% | 1,190,999 |
24-03-26 | 21.44 | -4.46% | 1,248,893 |
24-03-25 | 22.44 | -0.62% | 825,478 |
24-03-22 | 22.58 | -1.31% | 1,076,996 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.13% | 2.02B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |